Remove topic formulation-and-drug-delivery-controlled-release
article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way to resolution.

article thumbnail

mRNA therapeutics: a limitless revolution in medicine

European Pharmaceutical Review

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Medicine 104
article thumbnail

Evaluating NMR relaxometry for antibody identification

European Pharmaceutical Review

This has led to applications with biopharmaceutical formulations and protein investigations. Of particular interest is the potential of using NMR relaxometry as a point of receipt technique to satisfy regulatory identity testing requirements for active pharmaceutical ingredients (API) and drug product materials.